Drugs / SEL-110
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03436732 | Feb 2018 → Apr 2019 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT02648269 | Dec 2015 → Dec 2016 | gout | Selecta Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02959918 | Oct 2016 → Dec 2018 | gout | Selecta Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEL-110 | “SVP-rapamycin (SEL-110)” NCT02959918 ↗ |
| Known as | ImmTOR | “tolerogenic nanoparticles containing sirolimus (rapamycin) (SEL-110; also called ImmTOR®)” PMID 37069364 ↗ Apr 2023 |
| Modality | Other / unclassified | “a single intravenous dose of SEL-110, a nanoparticle containing rapamycin” NCT02648269 ↗ |
| Route | Intravenous | “a single intravenous dose of SEL-110” NCT02648269 ↗ |